Abstract: Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in premature born babies, it is used for increasing autologous blood cell levels before blood transfusion, AIDS joined anemia (intensified by zidovudine), anemia joined with chronic inflammatory conditions such as rheumatoid arthritis(still in research phase). During the course of Erythropoietin treatment side effects have been noticed, that include multiple organ systems, and have different levels of frequency. Major number of studies shows connection between erythropoietin treatment and bone marrow aplasia, but small number of them states clearly defined side-effect that explains this phenomenon.
INTRODUCTION
Erythropoietin regulates the development of erythroid cell line from proerythroblast to erythrocyte. Loss of blood, and/or low tissue oxygen levels are the basic stimulus for its release into the bloodstream. Erythropoietin is produced in the juxtaglomerular cells of the kidney and for one small part in the macrophages. Basic effect of erythropoietin is to stimulate proliferation of erythrocyte precursor cells and create new erythrocytes. As a consequence of kidney disease, due to diminished erythropoietin synthesis, anemia can occur (1) .
Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes, caused by different etiologic factors, associated with abnormal kidney function and a progressive decline in glomerular filtration rate, often leading to the end stage renal disease (ESRD). Term end-stage renal disease represents a stage of CKD where the accumulation of toxins, fluid, and electrolytes normally excreted by the kidneys results in the uremic syndrome. This syndrome leads to death unless the toxins are removed by renal replacement therapy, using dialysis or kidney transplantation (2) . Anemia occurs in more than 80% of patients with compromised kidney function (3) . In patients with CKD the main cause of normocytic, normochromic anemia is insufficient erythropoietin production in damaged kidneys (4) . Factors contributing to the occurrence of anemia can be: loss of iron due to various diagnostic procedures, blood retention in the dialysis machine, gastrointestinal bleeding, hyperparathyroidism, acute and chronic inflammatory diseases, aluminum toxicity, lack of folic-acid (5).
In order to solve the problem of anemia in dialysis patients, a group of researchers in 1985 cloned a human gene for erythropoietin. Two years later, the successful results of this study were published by The New England Journal of Medicine, latter In 1989, FDA approved the use of this hormone, in patients with CKD on dialysis (6 (7) . Recombinant human erythropoietin has been present in clinical practice for more than 20 years, for therapeutic indications: anemia in renal failure, anemia during chemotherapy in malignant tumors, prevention of anemia occurring in preterm infants, an increase in autologous blood production before donation, anemia in AIDS, (potentiated by zidovudine), anemia in chronic inflammatory conditions such as rheumatoid arthritis (still in research phase) (8) .
Adverse effects of erythropoietin include: flu-like syndrome that is transient, hypertension, which can cause encephalopathy with headache disorientation and sometimes convulsions. Iron deficit can occur due to increased need for it caused by intense erythropoiesis. Increase in blood viscosity and hematocrit can also occur, which can lead to thrombosis. The emphasis in writing this paper will be the red cell aplasia due to the development of anti-erythropoietic antibodies during treatment with any erythropoietin medication (9) . The period between 1998 and 2001 was marked by an increased concern for safety of erythropoietin use, due to the increased number of registered cases of pure red cell aplasia caused by neutralizing, anti-erythropoietin antibodies. A severe anemia, resistant to erythropoietin therapy, has developed in this group of patients. Pure red cell aplasia (PRCA) was registered primarily in those patients who were treated with subcutaneous administration of erythropoietin alpha, and it is attributed to changes in the product stabilization formulation and failure to comply with the cold chain principle (7). Isolated red cell aplasia due to the use of erythropoietin is a bone marrow disease followed by severe anemia due to hypoplasia of erythroid lineage precursor cells. The other precursors are not affected by this disease, so the patients present with normochromic, normocytic anemia with values of thrombocytes and neutrocytes within the normal range (9) .
The aim of this paper is to analyze the available case reports of red cell aplasia due to erythropoietin use, evaluation of their quality and causality for each study separately.
MATERIAL AND METHOD
For the purposes of this systematic review article a search through PubMed database was performed. Before the search, the following criteria were set: in relation to the type of article -case report, in terms of availability -entire texts and in terms of population-humans were population in the searched studies. The search was carried out in November 2017 and the inclusion criteria were: Free full article, English language, Case report studies, Studies that describe the occurrence of bone marrow disorders due to erythropoietin use The exclusion criteria were: studies conducted on animals, studies that are not "case reports" designs, "Letters to editor", case reports available in the form of an abstract.
Only studies conducted on humans were taken into consideration, and there were no restrictions in terms of age and sex. Keyword searched: erythropoietin hematological side effects, resulting in 15 studies; anti-erythropoietin antibodies in the search result was 30 studies; erythropoietin inducted pure red cell aplasia, resulting in 18 studies. Several studies appeared as a result of the search after using all three keyword combinations, and the last used combination of keywords included all the studies that appeared as search results. The most important criteria for inclusion were related to the following aspects: the study had to have one to two case reports; these reports were related to bone marrow aplasia due to erythropoietin administration. Diagnostic data for the bone marrow aplasia was necessary, since this side effect of erythropoietin is the subject of research in this paper. This paper includes 8 different studies.
Studies that did not pass the selection deviated from the required design of the study and the desired intervention. Studies that showed series of cases were excluded. Also, studies in which, instead of the administration of erythropoietin, patients received another drug or bone marrow aplasia occurred as a result of another disease, were excluded.
RESULTS
The results of this review paper are shown in the table's bellow, for all the studies that met the inclusion criteria. The assessment of the volume of the documentation for each study equals the sum of the elements present; to indicate the presence, not the absence of an element. The aim is to determine whether the data in the study are complete in order to draw conclusions about the cause-and-effect relationship between drug use and the occurrence of an adverse event.
The assessment of the credibility of each study is equal as the sum of the elements present; to indicate the presence, not the absence of an element. The goal of the table is to display information about when and where the event occurred and who recorded it.
By looking at Table 2 ... We note that all selected studies contain information on the time and location of the adverse event, as well as information about a medical worker who has documented the undesirable effects. The presence of these data points to the significant credibility of the selected studies.The number of cases described in the analyzed studies: one case carries a grade of 1, while studies describing 2 or 3 cases carry a score of 2. Naranjo score was used to evaluate the cause-and-effect relationship between drug use and the occurrence of an adverse event. It contains questions relating to the time period between the use of the medicine and the occurrence of an adverse reaction, what happens after the cessation of use, or the re-administration of the drug, whether there are alternative causes for the occurrence of an adverse event, whether there is a laboratory confirmation, etc. Data extraction: The goal of the table is to synthesize data on each case analyzed, such as the patient's sex and age, the dose of erythropoietin, how long was the patient monitored and the outcome. 
DISCUSSION
The primary aim of this systematic review article was to conduct a detailed search of medical databases, selecting appropriate studies, and processing, and pooling the results of these studies, to answer the question of whether there is a connection between the use of erythropoietin and bone marrow aplasia. In addition, this paper has the task of examining the literature on the safety of the use of erythropoietin, assessing the seriousness of the undesirable effect, and the mechanism of their emergence. We can see that in all the selected studies, the time interval from the use of the drug to the occurrence of an adverse drug reaction is described. All studies also contain information on what happens after the cessation of the drug (Dechallenge), while (Rechallenge) has not been performed in any study. This points to the fact that doctors mostly avoid exposure of patients to drugs that are suspected of having caused an unwanted effect by prior use.
The average value of the evaluation of the quality of the study was 7.0. The results of this systematic review article in terms of causality are similar to the results of the previous studies on the same subject. The calculated mean value of Naranjo causality score is 6.6 (5-8 probable causality), we can conclude that there is a likely correlation between the use of erythropoietin and bone marrow aplasia. The average age of patients was 56.1 years (the oldest patient was 82 years old and the youngest 26 years old). Three patients were female, three male, while for two patients, data on age and sex were not given. Erythropoietin-induced bone marrow aplasia, as a serious (life-threatening) adverse effect, carries the risk of aplastic anemia and aggravation of disseminated intravascular coagulation, as described in the analyzed studies. Particularly sensitive patients are those who start erythropoietin therapy after receiving kidney transplant, in order to prevent anemia (15, 16) . The most used erythropoietin forms were erythropoietin alpha and beta (17). Erythropoietin was mostly used for described therapeutic indication which is anemia in patients on hemodialysis, one of the studies included patient on peritoneal dialysis which received erythropoietin (17).
Generally, the aplasia appeared several weeks (8 to 10 on average) after erythropoietin administration, which is explained by the lifetime of the erythrocytes synthesized prior to administration, which is about 120 days. After their degradation in the spleen, the bone marrow damaged by the use of erythropoietin would no longer produce new erythrocytes, and signs of anemia would appear (13). The first symptoms that caused these patients to visit their nephrologist or the general physician were dizziness, fatigue, decreased appetite and rapid heart rate. In suspected cases, routine blood tests in which decreased erythrocytes were observed (below 4-4.5*10 12 /l for women and 4.5-5*10 12 /l for men), decreased hemoglobin levels (below 120g/l) and hematocrit (below 0.45%) (17). The literature states that there is a mechanism of action that causes erythropoietin to cause bone marrow aplasia. Bone marrow aplasia, with a previously history of erythropoietin administration, must be confirmed by laboratory tests. These include measuring hemoglobin levels, hematocrit number of erythrocytes, and serum iron levels (13, 14, 15) . Therefore, each of the analyzed studies contained a mandatory laboratory confirmation for this adverse effect. In addition to these routine laboratory analyzes, for the final confirmation of erythropoietin-induced aplasia, staining of bone marrow samples was performed. Immunochemical methods and staining of bone marrow preparations, provided an explanation of the mechanism by which erythropoietin leads to bone marrow aplasia. This led to the detection of neutralizing anti-erythropoietin antibodies responsible for the occurrence of this adverse effect (13, 16, 17.) In order for the bone marrow to recover, it is necessary to exclude erythropoietin and administer immunosuppressant (cyclosporine) (17). To monitor the rate of recovery, an analysis of the number of reticulocytes was carried out which proved that after a certain period of time the bone marrow starts regenerating, producing the peripheral blood young erythrocytes-reticulocytes (13).
Considering that men physiologically have a higher number of erythrocytes due to hormonal status, bone marrow is regenerated faster in a male patients, as well as in younger patients compared to the older ones (17). As reported in the available literature, erythropoietin causes bone marrow aplasia rarely. In all cases after cessation of the drug that was suspected to lead to aplasia of the red cell line, the undesirable effect has withdrawn (10-17.) In all eight studies, there are no alternative causes that could trigger the investigated adverse event, which is of great importance for linking the investigated drug with an unwanted event. All of the above facts speak of the likely causality between the use of erythropoietin and the onset of bone marrow aplasia.
CONCLUSION
Treatment of anemia in dialysis patients with erythropoietin can, rarely leads to serious (life-threatening) adverse effects. Symptoms and signs of bone marrow aplasia can be recognized and prevented early by careful monitoring of the patients by the nephrologist or clinical pharmacologist. There is clear risk for occurrence of this adverse effect, so careful use and do-sing of erythropoietin are to be advised. It is also important to inform patients about the first symptoms of aplasia, but also to increase the involvement of healthcare professionals in terms of reporting this adverse effect to the National Pharmacovigilance Center.
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